Accuray Launches All-in-One Radiotherapy Solution With Advanced Capabilities Designed to Set a New Standard in Cancer Care
Accuray (NASDAQ: ARAY) has launched the Accuray Stellar Solution, an advanced all-in-one radiotherapy platform initially for the U.S. market. The solution integrates with the company's Radixact Treatment Delivery System and includes comprehensive tools for adaptive radiotherapy.
The system offers multiple delivery modalities including IMRT, SBRT, and SGRT, targeting various cancer types such as breast, prostate, lung, and head and neck cancers. Key features include ClearRT helical kVCT imaging, Synchrony technology for real-time motion tracking, PreciseART for offline adaptive protocols, and the new Adapt LTE powered by Accuray Cenos for treatment evaluation and training.
Accuray (NASDAQ: ARAY) ha lanciato la Accuray Stellar Solution, una piattaforma avanzata tutto-in-uno per la radioterapia, inizialmente sul mercato statunitense. La soluzione si integra con il Radixact Treatment Delivery System dell'azienda e comprende strumenti completi per la radioterapia adattativa. Il sistema offre diverse modalità di erogazione tra cui IMRT, SBRT e SGRT, mirate a vari tipi di cancro come seno, prostata, polmone e testa e collo. Le caratteristiche principali includono imaging a elica kVCT ClearRT, tecnologia Synchrony per il monitoraggio del movimento in tempo reale, PreciseART per protocolli adattativi offline, e la nuova Adapt LTE powered by Accuray Cenos per valutazione del trattamento e formazione.
Accuray (NASDAQ: ARAY) ha lanzado la Accuray Stellar Solution, una plataforma avanzada todo-en-uno de radioterapia, inicialmente para el mercado estadounidense. La solución se integra con el Radixact Treatment Delivery System de la empresa e incluye herramientas integrales para radioterapia adaptativa. El sistema ofrece múltiples modalidades de entrega, incluyendo IMRT, SBRT y SGRT, para varios tipos de cáncer como de mama, próstata, pulmón y cabeza y cuello. Entre sus características destacan imagen kVCT helicoidal ClearRT, tecnología Synchrony para seguimiento del movimiento en tiempo real, PreciseART para protocolos adaptativos offline y la nueva Adapt LTE impulsada por Accuray Cenos para evaluación del tratamiento y entrenamiento.
Accuray (NASDAQ: ARAY)은 미국 시장을 시작으로 사용할 고급 올인원 방사선 치료 플랫폼인 Accuray Stellar Solution를 출시했습니다. 이 솔루션은 회사의 Radixact Treatment Delivery System와 통합되며 적응 방사선 치료를 위한 포괄적인 도구를 포함합니다. 시스템은 IMRT, SBRT, SGRT를 포함한 다양한 전달 모드를 제공하며 유방, 전립선, 폐, 두경부 등 여러 암 유형을 대상으로 합니다. 주요 특징으로는 ClearRT 나선형 KVCT 영상, 실시간 움직임 추적을 위한 Synchrony 기술, 오프라인 적응 프로토콜용 PreciseART, 치료 평가 및 교육용으로 새로 추가된 Adapt LTE powered by Accuray Cenos가 있습니다.
Accuray (NASDAQ: ARAY) a lancé la Accuray Stellar Solution, une plateforme de radiothérapie tout-en-un avancée, initialement pour le marché américain. La solution s'intègre au Radixact Treatment Delivery System de l'entreprise et comprend des outils complets pour la radiothérapie adaptative. Le système offre plusieurs modalités de délivrance dont IMRT, SBRT et SGRT, ciblant divers cancers tels que le sein, la prostate, le poumon et les cancers de la tête et du cou. Caractéristiques clés : imagerie kVCT hélicoïdal ClearRT, technologie Synchrony pour le suivi du mouvement en temps réel, PreciseART pour des protocoles adaptatifs hors ligne, et la nouvelle Adapt LTE powered by Accuray Cenos pour l'évaluation du traitement et la formation.
Accuray (NASDAQ: ARAY) hat die Accuray Stellar Solution eingeführt, eine fortschrittliche All-in-One-Strahlenbehandlungsplattform, zunächst für den US-Markt. Die Lösung lässt sich in das Radixact Treatment Delivery System des Unternehmens integrieren und umfasst umfassende Werkzeuge für adaptive Strahlentherapie. Das System bietet mehrere Erzielungsmodi, darunter IMRT, SBRT und SGRT, und richtet sich an verschiedene Krebsarten wie Brust-, Prostata-, Lungen- und Kopf-Hals-Krebs. Wichtige Merkmale sind ClearRT spiralförmige KVCT-Bildgebung, Synchrony-Technologie zur Echtzeit-Bewegungsüberwachung, PreciseART für Offline-Adaptive-Protokolle und das neue Adapt LTE powered by Accuray Cenos zur Behandlungsbewertung und Schulung.
Accuray (NASDAQ: ARAY) أطلقت Accuray Stellar Solution، منصة علاج إشعاعي متقدمة كل-في-واحد، مبدئياً لسوق الولايات المتحدة. تتكامل الحلول مع نظام توصيل العلاج Radixact من الشركة وتشمل أدوات شاملة للعلاج الإشعاعي التكيّفي. يوفر النظام عدة أساليب توصيل بما في ذلك IMRT و SBRT و SGRT، ويستهدف أنواع سرطان مختلفة مثل الثدي والبروستاتا والرئة ورأس وعنق. تشمل الميزات الرئيسية تصوير ClearRT KVCT الحلزوني، تكنولوجيا Synchrony لرصد الحركة في الوقت الحقيقي، PreciseART لبروتوكولات التكيّف دون اتصال، و< b>Adapt LTE powered by Accuray Cenos الجديد لتقييم العلاج والتدريب.
Accuray (NASDAQ: ARAY) 已推出 Accuray Stellar Solution，一款先进的全能放射治疗平台，最初面向美国市场。该解决方案与公司的 Radixact 治疗传递系统 集成，并包含用于自适应放射治疗的综合工具。系统提供多种给药模式，包括 IMRT、SBRT 和 SGRT，覆盖乳腺、前列腺、肺部以及头颈部等多种癌症类型。主要特点包括 ClearRT 螺旋 KVCT 成像、用于实时运动追踪的 Synchrony 技术、用于离线自适应协议的 PreciseART，以及用于治疗评估和培训的全新 Adapt LTE powered by Accuray Cenos。
- Introduction of comprehensive adaptive radiotherapy solution with multiple delivery modalities
- Integration capabilities with proprietary and vendor partner technologies expanding treatment options
- Advanced imaging technology (ClearRT) enabling better clinical decision-making
- New Adapt LTE feature for treatment evaluation and clinical training
- Initial availability limited to US market only
- Product subject to international regulatory approvals
- Substantial outstanding indebtedness mentioned in risk factors
Insights
Accuray's new Stellar system strengthens their radiotherapy portfolio with adaptive capabilities that could drive adoption and market share gains.
Accuray has unveiled their new Stellar Solution, a significant advancement in their radiotherapy product portfolio. This system represents more than just new hardware—it's a comprehensive platform designed to simplify and enhance adaptive radiotherapy, a growing approach that allows for treatment modifications based on changes in tumor characteristics during the treatment course.
The Stellar solution's key technical advantage comes from integrating multiple delivery modalities (IMRT, SBRT, SGRT) with the company's proprietary ClearRT helical kVCT imaging technology, providing the high-resolution imaging necessary for precise adaptive treatments. The platform incorporates Accuray's Synchrony technology for real-time motion tracking, PreciseART for offline adaptation, and an interface ready for online adaptive radiotherapy—covering the full spectrum of adaptive approaches.
A notable innovation is the Adapt LTE tool powered by Accuray Cenos, which allows clinicians to retrospectively evaluate delivered treatment plans against original objectives. This creates a learning environment where medical teams can build confidence in adaptive approaches before full implementation.
This launch strategically positions Accuray in the rapidly evolving radiotherapy market, where adaptive techniques are gaining clinical adoption but implementation complexity has been a barrier. By focusing on integration and workflow simplification, Accuray is addressing real clinical pain points while expanding their addressable market to include more complex treatment scenarios like total marrow irradiation.
The announcement comes just before the ASTRO Annual Meeting, maximizing visibility within the radiation oncology community and potentially accelerating early adoption among key opinion leaders.
The Accuray Stellar launch represents a strategic market positioning move in the competitive radiation therapy equipment sector. Accuray is clearly targeting the high-growth adaptive radiotherapy segment—which commands premium pricing due to its clinical advantages in treatment precision and potentially improved patient outcomes.
What's financially significant is how Accuray has packaged this as an integrated solution rather than standalone hardware. This approach typically yields higher margins and creates multiple revenue streams through the hardware, software, and potential service components. The comprehensive nature of the Stellar solution also creates natural barriers to competitive displacement once installed in a clinical setting.
The timing of this launch aligns with growing clinical evidence supporting adaptive approaches, particularly in complex cancer cases. Accuray's emphasis on making adaptive therapy more accessible and practical addresses a key market need, as radiation oncology departments seek technologies that maximize both clinical value and operational efficiency.
Strategically, Accuray is leveraging its existing installed base of Radixact systems, as Stellar appears to be a configuration of this platform with enhanced capabilities. This approach typically reduces development costs and accelerates market adoption compared to entirely new systems.
The educational component (Adapt LTE) demonstrates market savvy—addressing the learning curve barrier that often slows adoption of advanced radiotherapy techniques. This could accelerate utilization rates post-installation, potentially leading to earlier realization of the full revenue potential of each system placement.
While specific pricing information isn't provided, the comprehensive nature of this solution suggests it will command premium positioning in Accuray's product portfolio, potentially lifting average selling prices and gross margins.
New Solution Provides an Unprecedented Set of Tools, Empowering Clinical Teams With Choice and Flexibility to Deliver Adaptive Care—Tailoring Radiotherapy to Each Patient's Unique Needs
The Accuray Stellar solution, a configuration of the Radixact® Treatment Delivery System, will be featured at Accuray booth #525 during the 2025 American Society for Radiation Oncology (ASTRO) Annual Meeting in
"Innovations in radiation medicine, such as adaptive radiotherapy, are enabling clinicians to deliver more precise treatments that can lead to better tumor control and potentially higher survival rates. Our goal with Accuray Stellar is to provide tools that make it simple, fast and practical for medical teams to adopt adaptive radiotherapy techniques where needed, regardless of the stage of the patient's cancer journey. The solution reflects our commitment to innovating with purpose and compassion, and to redefining what's possible in personalized, radiotherapy treatments," said Suzanne Winter, president and CEO of Accuray.
To broaden the reach of transformative cancer care, Accuray Stellar easily integrates with the company's proprietary software and hardware solutions ― and vendor partner technologies ― expanding the range of available radiation delivery options and streamlining the treatment workflow for each patient.
With Accuray Stellar, clinicians have access to a solution capable of the full range of delivery modalities, from image-guided radiation therapy (IMRT) to stereotactic body radiation therapy (SBRT) treatments and surface-guided ration therapy (SGRT), to optimize outcomes for standard radiation therapy indications including breast, prostate, lung, and head and neck cancers, in addition to complex treatments such as total marrow irradiation.
Accuray Stellar provides a unique option for accurately delivering radiation while correcting for changes in the size or shape of the tumor, and patient or tumor movement, that can occur while patients undergo care. The solution offers a versatile and simplified path to adaptive radiotherapy developed to provide the foundation for adaptive care that can evolve with each patient's needs. The adaptive suite ranges from real-time motion tracking and correction, with Synchrony® technology, to offline adaptive protocols featuring PreciseART®, as well as an online-adaptive ready interface (a prerequisite for OART**), providing the foundation for adaptive care that evolves with each patient's needs.
Medical care teams can also leverage one of the company's latest innovations, Adapt LTE*** powered by Accuray Cenos, only available on Accuray Stellar. Adapt LTE retrospectively evaluates previously delivered Accuray Precision treatment plans against original therapy objectives. It leverages adaptive tools to analyze historical treatment data to help clarify clinical decision pathways. It is designed for training purposes or post-treatment evaluation, enabling clinicians to build greater confidence and consistency in planning, contouring, and determining the appropriate use of adaptive technologies. This is a tool that allows clinicians to learn, trial and evaluate.
ClearRT® helical kVCT imaging provides the foundation for Accuray adaptive radiotherapy technology. ClearRT is designed to acquire high resolution images with ease and speed, providing healthcare professionals with exceptional clarity of the tumor and surrounding anatomy. Better clarity in imaging will enable clinicians to make more informed decisions about all aspects of the patient's treatment and helps improve the quality of care for almost any patient who would benefit from radiotherapy.
About Accuray
Accuray is committed to expanding the powerful potential of radiation therapy to improve as many lives as possible. We invent unique, market-changing solutions designed to deliver radiation treatments for even the most complex cases—while making commonly treatable cases even easier—to meet the full spectrum of patient needs. We are dedicated to continuous innovation in radiation therapy for oncology, neuro-radiosurgery, and beyond, as we partner with clinicians and administrators, empowering them to help patients get back to their lives, faster. Accuray is headquartered in
Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to expectations regarding the company's products, clinical applications, clinical results, patient experiences and patient outcomes. These forward-looking statements involve risks and uncertainties. If any of these risks or uncertainties materialize, or if any of the company's assumptions prove incorrect, actual results could differ materially from the results expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the effect of the global macroeconomic environment on the operations of the company and those of its customers and suppliers; disruptions to our supply chain, including increased logistics costs; the company's ability to achieve widespread market acceptance of its products; substantial outstanding indebtedness and its ability to maintain compliance with financial covenants related to its debt; risks inherent in international operations; and such other risks identified under the heading "Risk Factors" in the company's Annual Report on Form 10-K, filed with the Securities and Exchange Commission (the "SEC") on August 28, 2025, and as updated periodically with the company's other filings with the SEC.
Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.
*The Accuray Stellar System is currently available for the US market and is subject to international regulatory approval or licensing processes such that the availability of these products may vary according to geographical location.
**OART stands for Online Adaptive Radiation Therapy
***Adapt LTE is currently available for the US market and is subject to international regulatory approval or licensing processes such that the availability of these products may vary according to geographical location. LTE stands for Learn, Trial, and Evaluate
Media Contact
Beth Kaplan
Public Relations Director, Accuray
bkaplan@accuray.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/accuray-launches-all-in-one-radiotherapy-solution-with-advanced-capabilities-designed-to-set-a-new-standard-in-cancer-care-302567915.html
SOURCE Accuray Incorporated
FAQ
What is the Accuray Stellar Solution and when will it be available?
What types of cancer can be treated with the Accuray Stellar system?
What are the key features of Accuray's new Stellar Solution?
How does the Accuray Stellar Solution improve cancer treatment?
What is Adapt LTE in the Accuray Stellar system?
